Teva Pharmaceutical Industries Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scroll to see more
Teva Pharmaceutical Industries Limited income statement - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue17.2616.5415.8514.9315.8816.6616.8918.85
Cost of Revenue8.328.488.207.958.288.939.3510.56
Gross Profit8.948.067.656.977.597.737.548.30
Operating Expenses
Research & Development1.011.000.950.840.971.001.011.21
Selling, General & Administrative3.973.703.503.453.533.673.814.21
Operating Expenses6.784.704.471.232.924.671.505.14
Operating Income2.163.363.18-2.201.723.06-0.443.16
Other Income/Expense
Interest Income0.000.000.070.010.000.100.000.00
Interest Expense0.921.00-1.030.930.89-0.900.000.96
Other Income/Expense-0.92-3.60-0.07-4.861.05-0.060.84-4.80
Income
Income Before Tax1.24-1.28-0.62-3.160.66-4.27-1.27-2.60
Income Tax Expense-0.180.68-0.01-0.640.21-0.17-0.28-0.20
Net Income1.41-1.64-0.56-2.450.42-3.99-1.00-2.15
Net Income - Continuous Operations1.41-1.96-0.62-2.500.460.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.000.00
EBITDA3.140.784.33-0.932.884.611.34-1.64
EBIT2.88-0.283.18-2.231.553.06-0.38-1.64
Depreciation & Amortization1.001.061.150.580.531.560.610.00
Earnings Per Share
Basic EPS1.00-1.00--2.00--4.00-1.00-2.00
Diluted EPS1.00-1.00--2.00--4.00-1.00-2.00
Basic Shares Outstanding1.151.131.121.111.101.101.090.00
Diluted Shares Outstanding1.171.131.121.111.111.101.090.00